GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $12,188.16 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,104 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $11.04, for a total transaction of $12,188.16. Following the completion of the transaction, the chief financial officer now owns 30,836 shares of the company’s stock, valued at $340,429.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 18th, Kevin Feeley sold 3,253 shares of GeneDx stock. The shares were sold at an average price of $10.59, for a total transaction of $34,449.27.

GeneDx Price Performance

Shares of WGS stock traded up $6.07 on Tuesday, reaching $17.07. The company’s stock had a trading volume of 7,282,556 shares, compared to its average volume of 325,185. GeneDx Holdings Corp. has a 12-month low of $1.16 and a 12-month high of $18.24. The company has a market capitalization of $444.67 million, a P/E ratio of -2.25 and a beta of 2.75. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.23. The stock’s 50 day simple moving average is $9.39 and its 200-day simple moving average is $5.09.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The company had revenue of $57.42 million for the quarter, compared to the consensus estimate of $57.00 million. As a group, equities analysts predict that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on WGS. The Goldman Sachs Group lifted their price target on shares of GeneDx to $11.00 and gave the company a “neutral” rating in a research report on Monday, April 15th. TD Cowen lifted their target price on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, BTIG Research raised their target price on GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday.

Institutional Trading of GeneDx

Hedge funds have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. grew its position in GeneDx by 99.4% in the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after acquiring an additional 9,944 shares in the last quarter. PFG Investments LLC bought a new position in shares of GeneDx during the 1st quarter worth $95,000. HighTower Advisors LLC increased its position in GeneDx by 14.1% during the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after purchasing an additional 29,361 shares during the period. Pathstone Family Office LLC raised its stake in GeneDx by 262.2% in the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after buying an additional 39,327 shares in the last quarter. Finally, Trellus Management Company LLC lifted its stake in shares of GeneDx by 55.0% during the 3rd quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after purchasing an additional 54,976 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.